Sevoflurane
Parkinson's Disease (PD)
RenJi HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Parkinson's Disease (PD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Acetyl-L-Cysteine Kurdistan University of Medical Sciences | Phase 2 | B |
ec5026 EicOsis Human Health Inc. | Phase 1/2 | CCC |
hnc364 Guangzhou Henovcom Bioscience Co. Ltd. | Phase 1 | CC |
RAMIFENTANYL RenJi Hospital | N/A | D |
S-Ketamine RenJi Hospital | N/A | D |
Same molecule, other indications
Sevoflurane is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →